Oral antibiotic treatment of staphylococcal bone and joint infections in adults

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 2, 2014, Pages 309-322

  Kim, Baek Nam ^a   Kim, Eu Suk ^b   Oh, Myoung Don ^c  

^a Inje University College of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Antimicrobial treatment; Infectious arthritis; Joint prosthesis; Orthopaedic fixation devices; Osteomyelitis; Staphylococcus

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; COTRIMOXAZOLE; FOSFOMYCIN; FUSIDIC ACID; LINCOSAMIDE; LINEZOLID; MACROLIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOGRAMIN DERIVATIVE; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC THERAPY; BONE AND JOINT INFECTIONS; DRUG EFFICACY; HUMAN; MONOTHERAPY; NONHUMAN; REVIEW; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION;

ANTIMICROBIAL TREATMENT; INFECTIOUS ARTHRITIS; JOINT PROSTHESIS; ORTHOPAEDIC FIXATION DEVICES; OSTEOMYELITIS; STAPHYLOCOCCUS;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; HUMANS; OSTEOMYELITIS; PROSTHESIS-RELATED INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 84892468494     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt374     Document Type: Review

References (157)

1. Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004; 364: 369-79.
2. ZimmerliW, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351: 1645-54.
3. Mathews CJ, Weston VC, Jones A et al. Bacterial septic arthritis in adults. Lancet 2010; 375: 846-55.
4. WidmerAF. Newdevelopments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis 2001; 33 Suppl 2: S94-106.
5. Stengel D, Bauwens K, Sehouli J et al. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis 2001; 1: 175-88.
6. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis 2005; 9: 127-38.
7. Conterno LO, da Silva Filho CR. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev 2009; issue 3:CD004439.
8. Darley ES, MacGowan AP. Antibiotic treatmentof Gram-positiveboneand joint infections. J Antimicrob Chemother 2004; 53: 928-35.
9. Trampuz A, Zimmerli W. Antimicrobial agents in orthopaedic surgery: prophylaxis and treatment. Drugs 2006; 66: 1089-105.
10. Trampuz A, Zimmerli W. Diagnosis and treatment of infections associated with fracture-fixation devices. Injury 2006; 37 Suppl 2: S59-66.
11. Zimmerli W. Clinical practice. Vertebral osteomyelitis. NEngl JMed2010;362: 1022-9.
12. ShirtliffME, Mader JT. Acute septic arthritis. Clin Microbiol Rev 2002; 15:527-44.
13. Gouliouris T, Aliyu SH, Brown NM. Spondylodiscitis: update on diagnosis and management. J Antimicrob Chemother 2010; 65 Suppl 3: iii11-24.
14. Osmon DR, Berbari EF, Berendt AR et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2013; 56: e1-25.
15. Zimmerli W, Widmer AF, Blatter Met al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998;279: 1537-41.
16. Darley ES, Bannister GC, Blom AWet al. Role of early intravenous to oral antibiotic switch therapy in the management of prosthetic hip infection treated with one-or two-stage replacement. J Antimicrob Chemother 2011; 66: 2405-8.
17. Paakkonen M, Peltola H. Antibiotic treatment for acute haematogenous osteomyelitis of childhood: moving towards shorter courses and oral administration. Int J Antimicrob Agents 2011; 38: 273-80.
18. Le Saux N, Howard A, Barrowman NJ et al. Shorter courses of parenteral antibiotic therapy do not appear to influence response rates for children with acute hematogenous osteomyelitis: a systematic review. BMC Infect Dis 2002; 2: 16.
19. Calhoun JH, Manring MM. Adult osteomyelitis. Infect Dis Clin North Am 2005; 19: 765-86.
20. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-22.
21. Sampedro MF, Patel R. Infections associated with long-term prosthetic devices. Infect Dis Clin North Am 2007; 21: 785-819.
22. Widmer AF, Frei R, Rajacic Z et al. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis 1990; 162: 96-102.
23. Sendi P, ZimmerliW. Antimicrobial treatment concepts for orthopaedic device-related infection. Clin Microbiol Infect 2012; 18: 1176-84.
24. Landersdorfer CB, Bulitta JB, KinzigMet al. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 2009; 48: 89-124.
25. Ferry T, Uckay I, Vaudaux P et al. Risk factors for treatment failure in orthopedic device-related methicillin-resistant Staphylococcus aureus infection. Eur J Clin Microbiol Infect Dis 2010; 29: 171-80.
26. Zimmerli W, Frei R, Widmer AF et al. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother 1994; 33: 959-67.
27. Dworkin R, Modin G, Kunz S et al. Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. Antimicrob Agents Chemother 1990; 34: 1014-6.
28. Lucet JC, Herrmann M, Rohner Pet al. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1990; 34: 2312-7.
29. Muller-Serieys C, Saleh Mghir A, Massias L et al. Bactericidal activity of the combination of levofloxacin with rifampin in experimental prosthetic knee infection in rabbits due to methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53: 2145-8.
30. Baldoni D, Haschke M, Rajacic Z et al. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob Agents Chemother 2009; 53: 1142-8.
31. Murillo O, Pachon ME, EubaGet al. Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection. Antimicrob Agents Chemother 2008; 52: 3681-6.
32. Vergidis P, Rouse MS, Euba G et al. Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis. Antimicrob Agents Chemother 2011; 55: 1182-6.
33. Norden CW, Keleti E. Treatment of experimental staphylococcal osteomyelitis with rifampin and trimethoprim, alone and in combination. Antimicrob Agents Chemother 1980; 17: 591-4.
34. O'Reilly T, Kunz S, Sande E et al. Relationship between antibiotic concentration in bone and efficacy of treatment of staphylococcal osteomyelitis in rats: azithromycin compared with clindamycin and rifampin. Antimicrob Agents Chemother 1992; 36: 2693-7.
35. Isiklar ZU, Darouiche RO, LandonGCet al. Efficacy of antibiotics alone for orthopaedic device related infections. Clin Orthop Relat Res 1996; 184-9.
36. ShirtliffME, Mader JT, Calhoun J. Oral rifampin plus azithromycin or clarithromycin to treat osteomyelitis in rabbits. Clin Orthop Relat Res 1999; 229-36.
37. Vaudaux P, Francois P, Bisognano C et al. Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46: 1503-9.
38. ShirtliffME, Calhoun JH, Mader JT. Comparative evaluation of oral levofloxacin and parenteral nafcillin in the treatment of experimental methicillin-susceptible Staphylococcus aureus osteomyelitis in rabbits. J Antimicrob Chemother 2001; 48: 253-8.
39. Murillo O, Domenech A, Garcia A et al. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2006; 50: 4011-7.
40. Grossi O, Caillon J, Arvieux C et al. Invivo efficacy of moxifloxacin compared with cloxacillin and vancomycin in a Staphylococcus aureus rabbit arthritis experimental model. Antimicrob Agents Chemother 2007; 51: 3401-3.
41. Monzon M, Garcia-Alvarez F, Lacleriga A et al. A simple infection model using pre-colonized implants to reproduce rat chronic Staphylococcus aureus osteomyelitis and study antibiotic treatment. J Orthop Res 2001;19: 820-6.
42. ShirtliffME, Calhoun JH, Mader JT. Gatifloxacin efficacy in treatment of experimental methicillin-sensitive Staphylococcus aureus-induced osteomyelitis in rabbits. Antimicrob Agents Chemother 2002; 46: 231-3.
43. Patel R, Piper KE, Rouse MS et al. Linezolid therapy of Staphylococcus aureus experimental osteomyelitis. Antimicrob Agents Chemother 2000;44: 3438-40.
44. Norden CW, Shinners E, Niederriter K. Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus. J Infect Dis 1986; 153: 956-9.
45. Saginur R, Stdenis M, Ferris W et al. Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections. Antimicrob Agents Chemother 2006; 50: 55-61.
46. Aubry-Damon H, Soussy CJ, Courvalin P. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1998; 42: 2590-4.
47. O'Neill AJ, Cove JH, Chopra I. Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J Antimicrob Chemother 2001; 47: 647-50.
48. Fraimow HS. Systemic antimicrobial therapy in osteomyelitis. Semin Plast Surg 2009; 23: 90-9.
49. Schwank S, Rajacic Z, Zimmerli W et al. Impact of bacterial biofilm formation on in vitro and in vivo activities of antibiotics. Antimicrob Agents Chemother 1998; 42: 895-8.
50. Fong IW, Ledbetter WH, Vandenbroucke AC et al. Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicrob Agents Chemother 1986; 29: 405-8.
51. RimmeleT, Boselli E, BreilhDet al. Diffusion of levofloxacin into boneand synovial tissues. J Antimicrob Chemother 2004; 53: 533-5.
52. Malincarne L, Ghebregzabher M, Moretti MV et al. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. J Antimicrob Chemother 2006; 57: 950-4.
53. Metzler K, Hansen GM, Hedlin P et al. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and-resistant Staphylococcus aureus. Int J Antimicrob Agents 2004; 24: 161-7.
54. Blumberg HM, Rimland D, Carroll DJ et al. Rapid development of ciprofloxacin resistance in methicillin-susceptible and-resistant Staphylococcus aureus. J Infect Dis 1991; 163: 1279-85.
55. Murillo O, Pachon ME, Euba G et al. High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. J Infect 2009; 58: 220-6.
56. OzturanKE, Yucel I, Kocoglu Eet al. Efficacyofmoxifloxacincomparedto teicoplanin in the treatment of implant-related chronic osteomyelitis in rats. J Orthop Res 2010; 28: 1368-72.
57. Dellamonica P, Bernard E, Etesse H et al. Evaluation of pefloxacin, ofloxacin and ciprofloxacin in the treatment of thirty-nine cases of chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 1989; 8: 1024-30.
58. Gentry LO, Rodriguez GG. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother 1990; 34: 40-3.
59. San Juan R, Garcia-Reyne A, Caba P et al. Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections. Antimicrob Agents Chemother 2010; 54:5161-6.
60. Howden BP, Grayson ML. Dumb and dumber-the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 2006; 42: 394-400.
61. Turnidge J. Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 1999; 12 Suppl 2: S23-34.
62. Turnidge J, Collignon P. Resistance to fusidicacid. Int J AntimicrobAgents 1999; 12 Suppl 2: S35-44.
63. Hierholzer G, Rehn J, Knothe H et al. Antibiotic therapy of chronic post-traumatic osteomyelitis. J Bone Joint Surg Br 1974; 56-B: 721-9.
64. Coombs RR, Menday AP. Fusidic acid in orthopaedic infections due to coagulase-negative staphylococci. Curr Med Res Opin 1985; 9: 587-90.
65. Turnidge J, Grayson ML. Optimum treatment of staphylococcal infections. Drugs 1993; 45: 353-66.
66. Atkins B, Gottlieb T. Fusidic acid in bone and joint infections. Int J Antimicrob Agents 1999; 12 Suppl 2: S79-93.
67. Wang JL, Tang HJ, Hsieh PH et al. Fusidic acid for the treatment of bone and joint infections caused by meticillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2012; 40: 103-7.
68. Clemett D, Markham A. Linezolid. Drugs 2000; 59: 815-27.
69. Kutscha-Lissberg F, Hebler U, Muhr G et al. Linezolid penetration into bone and joint tissues infected with methicillin-resistant staphylococci. Antimicrob Agents Chemother 2003; 47: 3964-6.
70. Rana B, Butcher I, Grigoris P et al. Linezolid penetration into osteo-articular tissues. J Antimicrob Chemother 2002; 50: 747-50.
71. Gerson SL, Kaplan SL, Bruss JB et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46:2723-6.
72. Rho JP, Sia IG, Crum BA et al. Linezolid-associated peripheral neuropathy. Mayo Clin Proc 2004; 79: 927-30.
73. Broder KW, Moise PA, Schultz RO et al. Clinical experience with linezolid in conjunction with wound coverage techniques for skin and soft-tissue infections and postoperative osteomyelitis. Ann Plast Surg 2004; 52:385-90.
74. Bassetti M, Vitale F, Melica G et al. Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother 2005;55: 387-90.
75. Aneziokoro CO, Cannon JP, Pachucki CT et al. The effectiveness and safety of oral linezolid for the primary and secondary treatment of osteomyelitis. J Chemother 2005; 17: 643-50.
76. Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. Diagn Microbiol Infect Dis 2007; 59: 173-9.
77. Vercillo M, Patzakis MJ, Holtom P et al. Linezolid in the treatment of implant-related chronic osteomyelitis. Clin Orthop Relat Res 2007; 461:40-3.
78. Messina AF, Namtu K, Guild M et al. Trimethoprim-sulfamethoxazole therapy for children with acute osteomyelitis. Pediatr Infect Dis J 2011;30: 1019-21.
79. Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008;46: 584-93.
80. Grim SA, Rapp RP, Martin CA et al. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2005; 25: 253-64.
81. Yeldandi V, Strodtman R, Lentino JR. In-vitro and in-vivo studies of trimethoprim-sulphamethoxazole against multiple resistant Staphylococcus aureus. J Antimicrob Chemother 1988; 22: 873-80.
82. Saux MC, Le Rebeller A, Leng B et al. Bone diffusion of trimethoprim and sulfamethoxazole high pressure liquid chromatography (HPLC) (author's transl). Pathol Biol (Paris) 1982; 30: 385-8.
83. Sattar MA, Cawley MI, Holt JE et al. The penetration of trimethoprim and sulphamethoxazole into synovial fluid. J Antimicrob Chemother 1983; 12:229-33.
84. Adra M, Lawrence KR. Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections. Ann Pharmacother 2004; 38:338-41.
85. Stein A, Bataille JF, Drancourt M et al. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob Agents Chemother 1998; 42: 3086-91.
86. Garau J, Bouza E, Chastre J et al. Management of methicillin-resistant Staphylococcus aureus infections. Clin Microbiol Infect 2009; 15: 125-36.
87. Levin TP, Suh B, Axelrod P et al. Potential clindamycin resistance in clindamycin-susceptible, erythromycin-resistant Staphylococcus aureus: report of a clinical failure. Antimicrob Agents Chemother 2005; 49: 1222-4.
88. Siberry GK, Tekle T, Carroll K et al. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37: 1257-60.
89. Martinez-Aguilar G, Avalos-Mishaan A, Hulten K et al. Communityacquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2004;23: 701-6.
90. Peltola H, Paakkonen M, Kallio P et al. Clindamycin vs. first-generation cephalosporins for acute osteoarticular infections of childhood-a prospective quasi-randomized controlled trial. Clin Microbiol Infect 2012;18: 582-9.
91. Pontifex AH, McNaught DR. The treatment of chronic osteomyelitis with clindamycin. Can Med Assoc J 1973; 109: 105-7.
92. Toma MB, Smith KM, Martin CA et al. Pharmacokinetic considerations in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. Orthopedics 2006; 29: 497-501.
93. Gemmell CG, Edwards DI, Fraise AP et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57: 589-608.
94. Maskell JP, Sefton AM, Yong J et al. Comparative in-vitro activity of erythromycin, vancomycin and pristinamycin. Infection 1988; 16: 365-70.
95. Reid AB, Daffy JR, Stanley P et al. Use of pristinamycin for infections by Gram-positive bacteria: clinical experience at an Australian hospital. Antimicrob Agents Chemother 2010; 54: 3949-52.
96. Ng J, Gosbell IB. Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp. J Antimicrob Chemother 2005; 55: 1008-12.
97. Ruhe JJ, Monson T, Bradsher RWet al. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005; 40: 1429-34.
98. Minuth JN, Holmes TM, Musher DM. Activity of tetracycline, doxycycline, and minocycline against methicillin-susceptible and-resistant staphylococci. Antimicrob Agents Chemother 1974; 6: 411-4.
99. Dasgupta MK, Shishido H, Salama S et al. The effects of macrolide and quinolone antibiotics in methicillin-resistant Staphylococcus aureus biofilm growth. Adv Perit Dial 1997; 13: 214-7.
100. Lode H. The pharmacokinetics of azithromycin and their clinical significance. Eur J Clin Microbiol Infect Dis 1991; 10: 807-12.
101. Falagas ME, Giannopoulou KP, Kokolakis GN et al. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008;46: 1069-77.
102. Roussos N, Karageorgopoulos DE, Samonis G et al. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int J Antimicrob Agents 2009; 34: 506-15.
103. Schintler MV, Traunmuller F, Metzler J et al. High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother 2009;64: 574-8.
104. Poeppl W, Tobudic S, Lingscheid T et al. Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2011; 55: 931-3.
105. Monzon M, Oteiza C, Leiva J et al. Synergy of different antibiotic combinations in biofilms of Staphylococcus epidermidis. J Antimicrob Chemother 2001; 48: 793-801.
106. Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis 2012; 54: 393-407.
107. Nungu KS, Larsson S, Wallinder L et al. Bone and wound fluid concentrations of cephalosporins. Oral cefadroxil and parenteral cefuroxime compared in 52 patients with a trochanteric fracture. Acta Orthop Scand 1995; 66: 161-5.
108. Cohen R, Grimprel E. Pharmacokinetics and pharmacodynamics of antimicrobial therapy used in child osteoarticular infections. Arch Pediatr 2007; 14 Suppl 2: S122-7.
109. Gisby J, Beale AS, Bryant JE et al. Staphylococcal osteomyelitis-a comparison of co-amoxiclav with clindamycin and flucloxacillin in an experimental rat model. J Antimicrob Chemother 1994; 34: 755-64.
110. Cole WG, Dalziel RE, Leitl S. Treatment of acute osteomyelitis in childhood. J Bone Joint Surg Br 1982; 64: 218-23.
111. Kolyvas E, Ahronheim G, Marks MI et al. Oral antibiotic therapy of skeletal infections in children. Pediatrics 1980; 65: 867-71.
112. TetzlaffTR, McCracken GH Jr, Nelson JD. Oral antibiotic therapy for skeletal infections of children. II. Therapy of osteomyelitis and suppurative arthritis. J Pediatr 1978; 92: 485-90.
113. Bachur R, Pagon Z. Success ofshort-courseparenteralantibiotic therapy for acute osteomyelitis of childhood. Clin Pediatr (Phila) 2007; 46: 30-5.
114. Grimprel E, Lorrot M, Haas H et al. Osteoarticular infections: therapeutic proposals of the Paediatric Infectious Diseases Group of the French Society of Paediatrics (GPIP). Arch Pediatr 2008; 15 Suppl 2: S74-80.
115. Rao N, Ziran BH, Lipsky BA. Treating osteomyelitis: antibiotics and surgery. Plast Reconstr Surg 2011; 127 Suppl 1: 177S-87S.
116. Davis JS. Management of bone and joint infections due to Staphylococcus aureus. Intern Med J 2005; 35 Suppl 2: S79-96.
117. Haas DW, McAndrew MP. Bacterial osteomyelitis in adults: evolving considerations in diagnosis and treatment. Am J Med 1996; 101: 550-61.
118. Forrest GN, Tamura K. Rifampin combination therapy for nonmycobacterial infections. Clin Microbiol Rev 2010; 23: 14-34.
119. Perlroth J, Kuo M, Tan J et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature. Arch Intern Med 2008; 168: 805-19.
120. Lora-Tamayo J, Murillo O, IribarrenJA et al. Alarge multicenter studyof methicillin-susceptible-and methicillin-resistant-Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis 2012; 56: 182-94.
121. Achermann Y, Eigenmann K, Ledergerber B et al. Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched case-control study. Infection 2013; 41: 431-7.
122. Samuel JR, Gould FK. Prosthetic joint infections: single versus combination therapy. J Antimicrob Chemother 2010; 65: 18-23.
123. Drancourt M, Stein A, Argenson JN et al. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother 1993; 37: 1214-8.
124. Senneville E, Yazdanpanah Y, Cazaubiel M et al. Rifampicin-ofloxacin oral regimen for the treatment of mild to moderate diabetic foot osteomyelitis. J Antimicrob Chemother 2001; 48: 927-30.
125. Soriano A, Garcia S, Bori G et al. Treatment of acute post-surgical infection of joint arthroplasty. Clin Microbiol Infect 2006; 12: 930-3.
126. Frippiat F, Meunier F, Derue G. Place of newerquinolonesandrifampicin in the treatment of Gram-positive bone and joint infections. J Antimicrob Chemother 2004; 54: 1158; author reply 1159.
127. Torda AJ, Gottlieb T, Bradbury R. Pyogenic vertebral osteomyelitis: analysis of 20 cases and review. Clin Infect Dis 1995; 20: 320-8.
128. Drancourt M, Stein A, Argenson JN et al. Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin. J Antimicrob Chemother 1997; 39: 235-40.
129. Aboltins CA, Page MA, Buising KL et al. Treatment of staphylococcal prosthetic joint infections with debridement, prosthesis retention and oral rifampicin and fusidic acid. Clin Microbiol Infect 2007; 13: 586-91.
130. Nguyen S, Pasquet A, Legout L et al. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect 2009; 15: 1163-9.
131. Gomez J, Canovas E, Banos Vet al. Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant. Antimicrob Agents Chemother 2011; 55: 4308-10.
132. Euba G, Murillo O, Fernandez-Sabe N et al. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother 2009; 53: 2672-6.
133. Czekaj J, DinhA, MoldovanAet al. Efficacyofacombinedoral clindamycinrifampicin regimen for therapy of staphylococcal osteoarticular infections. Scand J Infect Dis 2011; 43: 962-7.
134. Neu HC. Synergy and antagonism of combinations with quinolones. Eur J Clin Microbiol Infect Dis 1991; 10: 255-61.
135. Rissing JP. Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones. Clin Infect Dis 1997; 25: 1327-33.
136. Senneville E, Joulie D, Legout L et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to Staphylococcus aureus. Clin Infect Dis 2011; 53: 334-40.
137. Schrenzel J, HarbarthS, SchockmelGet al. A randomizedclinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection. Clin Infect Dis 2004; 39:1285-92.
138. Barberan J, Aguilar L, Carroquino G et al. Conservative treatment of staphylococcal prosthetic joint infections in elderly patients. Am J Med 2006; 119: 993.e7-10.
139. Barberan J, Aguilar L, Gimenez MJ et al. Levofloxacin plus rifampicin conservative treatment of 25 early staphylococcal infections of osteosynthetic devices for rigid internal fixation. Int J Antimicrob Agents 2008; 32: 154-7.
140. Viale P, Furlanut M, Scudeller L et al. Treatment of pyogenic (nontuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin. Int J Antimicrob Agents 2009; 33: 379-82.
141. Peel TN, Buising KL, Dowsey MM et al. Outcome of debridement and retention in prosthetic joint infections bymethicillin-resistant staphylococci, with special reference to rifampin and fusidic acid combination therapy. Antimicrob Agents Chemother 2013; 57: 350-5.
142. Donaldson AD, Chan RC, Gosbell IB. Community-acquired methicillinresistant Staphylococcus aureus in bone and joint infections: development of rifampicin resistance. Med J Aust 2006; 184: 196.
143. Legout L, Valette M, Dezeque H et al. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?. J Antimicrob Chemother 2010; 65: 2224-30.
144. Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 2007; 27: 476-9.
145. Soriano A, Ortega M, Garcia S et al. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother 2007; 51: 2559-63.
146. Gruneberg RN, Emmerson AM. Prevention of emergence of bacterial resistance by combination of two antibiotics: rifampicin and trimethoprim. J Antimicrob Chemother 1980; 6: 349-56.
147. Zander J, Besier S, Faetke S et al. Antimicrobial activities of trimethoprim/sulfamethoxazole, 5-iodo-2'-deoxyuridine and rifampicin against Staphylococcus aureus. Int J Antimicrob Agents 2010; 36:562-5.
148. Clumeck N, Marcelis L, Amiri-Lamraski MH et al. Treatment of severe staphylococcal infections with a rifampicin-minocycline association. J Antimicrob Chemother 1984; 13 Suppl C: 17-22.
149. Norden CW, Fierer J, Bryant RE. Chronic staphylococcal osteomyelitis: treatment with regimens containing rifampin. Rev Infect Dis 1983; 5 Suppl 3: S495-501.
150. Littlewood-Evans AJ, Hattenberger M, Zak O et al. Effect of combination therapy of rifampicin and azithromycin on TNF levels during a rat model of chronic osteomyelitis. J Antimicrob Chemother 1997; 39: 493-8.
151. Collignon P, Turnidge J. Fusidic acid in vitro activity. Int J Antimicrob Agents 1999; 12 Suppl 2: S45-58.
152. Drugeon HB, Caillon J, Juvin ME. In-vitro antibacterial activity of fusidic acid alone and in combination with other antibiotics against methicillin-sensitive and-resistant Staphylococcus aureus. J Antimicrob Chemother 1994; 34: 899-907.
153. Goldstein EJ, Citron DM, Warren YA et al. Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and-susceptible S. aureus. J Med Microbiol 2008; 57: 452-6.
154. Leonard SN, KaatzGW, Rucker LR et al. Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2008; 62: 1305-10.
155. Learmonth ID, Dall G, Pollock DJ. Acute osteomyelitis and septic arthritis in children. A simple approach to treatment. S Afr Med J 1984; 65: 117-20.
156. GradosF, LescureFX, SennevilleEetal. Suggestions formanagingpyogenic (non-tuberculous) discitis in adults. Joint Bone Spine 2007; 74: 133-9.
157. Zeller V, Desplaces N. Antibiotherapy of bone and joint infections. Revue du Rhumatisme 2006; 73: 183-90.